Dharmacon, Inc., a unit of Fisher Biosciences has announced a settlement of its contract dispute with the Massachusetts Institute of Technology (MIT). As part of the agreement, MIT has dismissed all ...

RNA interference using small interfering RNAs (siRNAs) has become a mainstay of functional gene characterization and has generated over a dozen FDA-approved therapeutics and drugs in late-stage ...

Dharmacon's chemistry gets around that problem in a very elegant way," he said. Lashkari did not release details on the investment positions of the two funds. While Telegraph Hill focuses exclusively ...

Dharmacon, Inc., the world's leading supplier of innovative RNA and RNA interference (RNAi) research products, and GE Healthcare have entered into an exclusive distribution agreement in Japan for ...

Abbottt and Dharmacon, a unit of Fisher Biosciences, entered into a collaboration to develop new therapeutic agents based on gene-silencing technology of RNA interference (RNAi). “The research could ...

Revvity's Dharmacon All-in-one lentiviral platform has expanded to include whole-genome library options for CRISPR knockout (CRISPRko), CRISPR interference (CRISPRi), and CRISPR activation (CRISPRa).

LAFAYETTE, Colo.-- The Genome-Wide RNAi Global Initiative (RNAi Global), an alliance of Dharmacon, Inc., and 14 leading international research centers pioneering the use of whole-genome RNAi screening ...

Lentigen and Dharmacon, a unit of Fisher Biosciences, entered into a multiyear collaboration to develop and manufacture lentiviral expression reagents to deliver short hairpin RNA (shRNA) expression ...

The Dharmacon™ Edit-R™ Gene Engineering System is a novel platform for research which creates permanent and heritable gene disruption (knockouts) in cells utilizing the CRISPR-Cas9 gene engineering ...

GE Healthcare Dharmacon has launched today more than one million new CRISPR-Cas9 gene editing products using an advanced new algorithm to design highly functional and specific reagents targeting most ...